Breakthrough Therapies for Metastatic & Primary Cancers
Cherishing the moments that are meant to be.
Our multi-patented, ZetaMet™ (Zeta-BC-003) therapy is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone with the potential to increase survival rates.
Zetagen is focused on the 330,000 people in the United States and more globally, annually living with some form of bone metastases. We have created a series of novel therapies which address metastatic cancers at progressive stages. Our therapies are designed to suspend cancer, inhibit pain, and regenerate bone with the potential of increasing survival rates. These novel drugs from Zetagen are adjunctive to other cancer treatments and can be locally administered, to bone or soft tissue organs, when the lesion is first detected via a brief out-patient procedure. Pre-clinical studies and peer-review published data have shown the potential to reduce lesion size by 200% and in some cases completely resolve, reduce pain by 400+%, and improve mortality rates of 250%.
The U.S Food and Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Designations. Zetagen discovered and patented the first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. The small molecule has been approved by the FDA since 1971. Our research scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.